
Accretion Pharmaceuticals
NSE SME₹121,200 / 1200 Shares
IPO Live Subscription Details (times)
IPO Details
Accretion Pharmaceuticals IPO is priced between ₹96-101 per equity share, with a face value of ₹10 per share. The company's equity shares will be listed on the NSE SME, and Kfin Technologies Limited is managing the issue as the registrar.
The IPO bidding period opened on 14 May, 2025, and closed on 16 May, 2025. The allotment results will be announced on 19 May, 2025, with a tentative listing date set for 21 May, 2025.
The total issue comprises 29,46,000 shares, amounting to ₹29.75 Cr.
Accretion Pharmaceuticals IPO Highlights
IPO Date | Listing Date | Face Value | Price Band | Lot Size | Fresh Issue | Offer for Sale | Listing At |
---|---|---|---|---|---|---|---|
May 14, 2025 - May 16, 2025 | 21 May, 2025 | ₹10 Per Equity Share | ₹96-101 per equity share | - | Shares | - | NSE SME |
Accretion Pharmaceuticals IPO Timeline
Issue Price
₹96-101 per equity shareFace Value
₹10 Per Equity ShareListing at Group
NSE SMERegistrar
Kfin Technologies LimitedMarket Lot
1200 Shares (₹121,200/-)Lead Manager
Jawa Capital Services Private LimitedIssue Size
29,46,000 shares(aggregating up to ₹29.75 Cr)Retail Portion
Retail : 45%HNI : 45%QIB : 5%Subscription
7.67 timesAccretion Pharmaceuticals IPO Financial Information
Period Ended | Assets | Revenue | Profit After Tax | Net Worth | Reserves and Surplus | Total Borrowing |
---|---|---|---|---|---|---|
31 Dec 24 | 39.99 | 35.75 | 5.24 | 13.58 | 5.41 | 13.79 |
31 Mar 24 | 27.05 | 33.94 | 3.88 | 5.35 | 1.35 | 13.48 |
31 Mar 23 | 20.58 | 29.53 | 0.10 | 3.84 | 0.00 | 8.47 |
31 Mar 22 | 17.74 | 22.58 | 0.08 | 3.08 | 0.00 | 7.61 |
All values are in ₹ Cr.
Accretion Pharmaceuticals IPO Valuations
EPS PRE IPO ₹4.74/- | EPS POST IPO ₹6.28/- | PE PRE IPO 21.29 | PE POST IPO 16.08 | ROE 72.47% |
ROCE 36.73% | DEBT EQUITY 2.52 | RONW 72.47% | PAT MARGIN 11.51 | PRICE TO BOOK VALUE 7.55 |
About Company
Incorporated in 2012, Accretion Pharmaceuticals Limited is a pharmaceutical firm that produces and markets tablets, capsules, and other health care products.
The company provides contract manufacturing services as well. The Company produces and sells Tablets, Capsules, Oral Liquids, External Preparations (Ointment, Cream, Gel, Lotion, Medicated Shampoo, Mouthwash, Dusting Powder), and Oral Powder (Sachet, Dry Syrup).The company is also certified by ISO 9001:2015, ISO 14001:2015, and ISO 22000:2005, demonstrating its commitment towards quality and environmental management systems.
The manufacturing facility of the company is situated in Ahmedabad, Sanand, Gujarat.The company has spread its wings globally, representing itself in over 20 countries, with locations in Africa, Southeast Asia, as well as the Middle East.
Product Portfolio and Services:
Tablets and Capsules – Encompassing antibiotics, anti-inflammatory, pain management, cardiovascular, and gastrointestinal drugs.
Oral Liquids and Syrups – For respiratory, pediatric, and gastrointestinal treatments.
External Preparations – Such as medicated lotions, gels, ointments, and dusting powders for skin treatment and dermatological therapy.
Ayurvedic and Herbal Products – Emphasizing natural wellness remedies for immunity, digestion, and overall health.
As of January 2025, the company has 83 employees (including 4 Executive Directors) on its payroll.
Accretion Pharmaceuticals IPO Subscription Details
As on | QIB/NII | Retail | Total |
---|---|---|---|
Shares Offered / Reserved | 1,41,600 / 12,22,800 | 12,22,800 | 25,87,200 |
Day 1 - 14-05-25 06:00 PM | 0.00 / 0.51 x | 1.86 x | 1.12 x |
Day 2 - 15-04-25 06:00 PM | 0.75 / 0.92 x | 4.01 x | 2.37 x |
Day 3 - 16-05-25 06:00 PM | 12.14 / 4.28 x | 10.54 x | 7.67 x |
Accretion Pharmaceuticals IPO - Issue Objectives
- Capital expenditure towards purchase of new equipment/ machineries, etc.
- Capital expenditure towards upgradation of existing manufacturing facility
- Repayment/prepayme nt of certain borrowings availed by the Company
- Funding working capital requirements
- General Corporate Purpose
Accretion Pharmaceuticals
29 Xcelon Ind Park 1, B/h, Intas Pharmaceuticals, Vasna Chacharvad, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat,India, 382213Kfin Technologies Limited
Phone: 04067162222, 04079611000
Email: apl.ipo@kfintech.com